{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:19:47Z","timestamp":1772119187406,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Research Funds from Guangzhou Panyu Central Hospital","award":["PY-2023-007, PY-2023-010, PY-2023-026"],"award-info":[{"award-number":["PY-2023-007, PY-2023-010, PY-2023-026"]}]},{"name":"the Research Funds from Guangzhou Panyu Central Hospital","award":["PY-2023-007, PY-2023-010, PY-2023-026"],"award-info":[{"award-number":["PY-2023-007, PY-2023-010, PY-2023-026"]}]},{"name":"the Research Funds from Guangzhou Panyu Central Hospital","award":["PY-2023-007, PY-2023-010, PY-2023-026"],"award-info":[{"award-number":["PY-2023-007, PY-2023-010, PY-2023-026"]}]},{"name":"the Research Funds from Guangzhou Panyu Central Hospital","award":["PY-2023-007, PY-2023-010, PY-2023-026"],"award-info":[{"award-number":["PY-2023-007, PY-2023-010, PY-2023-026"]}]},{"name":"Guangdong Basic and Applied Basic Research Fund Enterprise Joint Fund","award":["2023A1515220024"],"award-info":[{"award-number":["2023A1515220024"]}]},{"DOI":"10.13039\/501100003785","name":"Medical Research Foundation of Guangdong Province","doi-asserted-by":"crossref","award":["2024070"],"award-info":[{"award-number":["2024070"]}],"id":[{"id":"10.13039\/501100003785","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Guangdong Hospital Pharmaceutical Research Fund project funding","award":["2024A31"],"award-info":[{"award-number":["2024A31"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s00210-024-03701-8","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T05:07:19Z","timestamp":1734325639000},"page":"6821-6829","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bioequivalence of cefdinir dispersible tablets in healthy Chinese subjects under fasting and fed conditions: a single-centred, randomized, open, single-dose, two-preparation, two-cycle, two-sequence, double-crossover trial"],"prefix":"10.1007","volume":"398","author":[{"given":"Nan","family":"Mao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuoheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianfen","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingna","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiajing","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diqun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianxing","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"issue":"12 Suppl","key":"3701_CR1","doi-asserted-by":"publisher","first-page":"S166","DOI":"10.1097\/00006454-200012001-00006","volume":"19","author":"M Adler","year":"2000","unstructured":"Adler M, McDonald PJ, Trostmann U, Keyserling C, Tack K (2000) Cefdinir vs. amoxicillin\/clavulanic acid in the treatment of suppurative acute otitis media in children. Pediatr Infect Dis J 19(12 Suppl):S166-170. https:\/\/doi.org\/10.1097\/00006454-200012001-00006","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"3701_CR2","doi-asserted-by":"publisher","first-page":"318","DOI":"10.4103\/0975-7406.120080","volume":"5","author":"S Bansal","year":"2013","unstructured":"Bansal S, Aggarwal G, Chandel P, Harikumar SL (2013) Design and development of cefdinir niosomes for oral delivery. J Pharm Bioallied Sci 5(4):318\u2013325. https:\/\/doi.org\/10.4103\/0975-7406.120080","journal-title":"J Pharm Bioallied Sci"},{"issue":"1\u20132","key":"3701_CR3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jchromb.2006.02.047","volume":"834","author":"ZJ Chen","year":"2006","unstructured":"Chen ZJ, Zhang J, Yu JC, Cao GY, Wu XJ, Shi YG (2006) Selective method for the determination of cefdinir in human plasma using liquid chromatography electrospray ionization tandam mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 834(1\u20132):163\u2013169. https:\/\/doi.org\/10.1016\/j.jchromb.2006.02.047","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"12","key":"3701_CR4","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1345\/aph.19407","volume":"34","author":"DR Guay","year":"2000","unstructured":"Guay DR (2000) Cefdinir: an expanded-spectrum oral cephalosporin. Ann Pharmacother 34(12):1469\u20131477. https:\/\/doi.org\/10.1345\/aph.19407","journal-title":"Ann Pharmacother"},{"issue":"Suppl 1","key":"3701_CR5","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/s1201-9712(03)90066-x","volume":"7","author":"MR Jacobs","year":"2003","unstructured":"Jacobs MR (2003) How can we predict bacterial eradication? Int J Infect Dis 7(Suppl 1):S13-20. https:\/\/doi.org\/10.1016\/s1201-9712(03)90066-x","journal-title":"Int J Infect Dis"},{"key":"3701_CR6","doi-asserted-by":"publisher","unstructured":"Khan A, Iqbal Z, Khan MI, Javed K, Khan A, Ahmad L,\u2026, Nasir F (2011) Simultaneous determination of cefdinir and cefixime in human plasma by RP-HPLC\/UV detection method: Method development, optimization, validation, and its application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 879(24):2423\u20132429. https:\/\/doi.org\/10.1016\/j.jchromb.2011.06.040","DOI":"10.1016\/j.jchromb.2011.06.040"},{"key":"3701_CR7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jchromb.2012.03.018","volume":"895\u2013896","author":"J Li","year":"2012","unstructured":"Li J, Wang L, Chen Z, Xie R, Li Y, Hang T, Fan G (2012) Development and validation of a rapid HPLC method for the determination of cefdinir in beagle dog plasma integrated with an automatic on-line solid-phase extraction following protein precipitation in the 96-well plate format. J Chromatogr B Analyt Technol Biomed Life Sci 895\u2013896:83\u201388. https:\/\/doi.org\/10.1016\/j.jchromb.2012.03.018","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"3701_CR8","doi-asserted-by":"publisher","unstructured":"Li Z, Liu J, Ju G, Yan K, Mao Y, Liu Q,\u2026, Qiu W (2021) Pharmacokinetics and bioequivalence evaluation of 2 formulations of tenofovir alafenamide. Clin Pharmacol Drug Dev 10(12):1519\u20131527. https:\/\/doi.org\/10.1002\/cpdd.985","DOI":"10.1002\/cpdd.985"},{"issue":"2","key":"3701_CR9","doi-asserted-by":"publisher","first-page":"Cd013099","DOI":"10.1002\/14651858.CD013099.pub2","volume":"2","author":"HS Lin","year":"2021","unstructured":"Lin HS, Lin PT, Tsai YS, Wang SH, Chi CC (2021) Interventions for bacterial folliculitis and boils (furuncles and carbuncles). Cochrane Database Syst Rev 2(2):Cd013099. https:\/\/doi.org\/10.1002\/14651858.CD013099.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"13","key":"3701_CR10","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.2165\/00003495-200464130-00004","volume":"64","author":"CM Perry","year":"2004","unstructured":"Perry CM, Scott LJ (2004) Cefdinir: a review of its use in the management of mild-to-moderate bacterial infections. Drugs 64(13):1433\u20131464. https:\/\/doi.org\/10.2165\/00003495-200464130-00004","journal-title":"Drugs"},{"issue":"1","key":"3701_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1586\/14787210.5.1.29","volume":"5","author":"HS Sader","year":"2007","unstructured":"Sader HS, Jones RN (2007) Cefdinir: an oral cephalosporin for the treatment of respiratory tract infections and skin and skin structure infections. Expert Rev Anti Infect Ther 5(1):29\u201343. https:\/\/doi.org\/10.1586\/14787210.5.1.29","journal-title":"Expert Rev Anti Infect Ther"},{"key":"3701_CR12","doi-asserted-by":"publisher","unstructured":"Su J, Zhang C, Su Y, Huang C, Zhao J, Yang H,\u2026, Yang X (2023) Pharmacokinetics, Bioequivalence, and safety evaluation of two formulations of 0.2-g ibuprofen granules. Clin Pharmacol Drug Dev 12(6):588\u2013593. https:\/\/doi.org\/10.1002\/cpdd.1211","DOI":"10.1002\/cpdd.1211"},{"issue":"14","key":"3701_CR13","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.13286\/j.1001-5213.2022.14.21","volume":"42","author":"H Su","year":"2022","unstructured":"Su H, Guo RC (2022) The background, implementation and outcome of the consistency evaluation of generic drugs. Chin Hosp Pharm J 42(14):1502\u20131505. https:\/\/doi.org\/10.13286\/j.1001-5213.2022.14.21","journal-title":"Chin Hosp Pharm J"},{"key":"3701_CR14","first-page":"152","volume":"03","author":"Z Wang","year":"2023","unstructured":"Wang Z, Dong X, Wang K, Feng Y, Luo Q, Yue X, Zhang L (2023) Comparison of efficacy and safety of national centralized volume-based procurement and original cefdinir oral normal-release preparations. Adv Drug React J 03:152\u2013158","journal-title":"Adv Drug React J"},{"key":"3701_CR15","doi-asserted-by":"publisher","unstructured":"Xu L, Su J, Muhetaer H, Zhang C, Huang C, Tang Y,\u2026, Liang Z (2023) Pharmacokinetic and Bioequivalence evaluation of two cefprozil dispersible tablets in healthy chinese volunteers. Clin Pharmacol Drug Dev 12(12):1229\u20131233. https:\/\/doi.org\/10.1002\/cpdd.1304","DOI":"10.1002\/cpdd.1304"},{"key":"3701_CR16","doi-asserted-by":"publisher","unstructured":"Zhang C, Shen Z, Li J, Wu Y, Xu Z, Gu W,\u2026, Su J (2023) Pharmacokinetics, bioequivalence, and safety evaluation of 2 formulations of 10-mg rivaroxaban tablets: a 4-period crossover trial. Clin Pharmacol Drug Dev 12(9):920\u2013926. https:\/\/doi.org\/10.1002\/cpdd.1261","DOI":"10.1002\/cpdd.1261"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03701-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-024-03701-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03701-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T06:47:37Z","timestamp":1748587657000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-024-03701-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["3701"],"URL":"https:\/\/doi.org\/10.1007\/s00210-024-03701-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4954921\/v1","asserted-by":"object"}]},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,16]]},"assertion":[{"value":"22 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This clinical trial was registered in the China Drug Trials Registry (\n                      \n                      ; registration number: CTR20210441; registration date: March 11, 2021). It was approved by the Ethics Committee of Panyu Central Hospital (Clinical Research Ethics Committee approval number: PYZXYYEC\u30102020\u2013029\u3011) and was conducted independently at the Phase I Clinical Trial Research Center of Panyu Central Hospital from March 15, 2021, to April 12, 2021. This study complied with the requirements of the Declaration of Helsinki (1989), Guidelines of Good Clinical Practice, and other related guiding principles.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the trial.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"There are no identifying details in this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}